Description: RXi Pharmaceuticals Corp is principally engaged in developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs.
Home Page: www.phiopharma.com
PHIO Technical Analysis
257 Simarano Drive
Marlborough,
MA
01752
United States
Phone:
508 767 3861
Officers
| Name | Title |
|---|---|
| Mr. Robert J. Bitterman | Interim Exec. Chairman |
| Dr. Geert Cauwenbergh Dr., Med.Sc., Ph.D. | Interim Principal Exec. & Financial Officer and Director |
| Ms. Caitlin Kontulis | VP of Fin. & Admin. and Sec. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0.2318 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3842 |
| Price-to-Sales TTM: | 48.0082 |
| IPO Date: | 2012-05-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 12 |